COUNT ON US
because your patients
are counting on you
Repatha® added to a statin can dramatically lower LDL-C and reduce the risk of another MI1
virtual product theater
Robust experience with Repatha®:
Data from clinical trials
and the real world
In addition to clinical trials, an estimated
>1,000,000
patients have received Repatha® in the
5 years since launch2,*
50
evolocumab clinical trials3
>47,000
patients were studied3,†
*Cumulative post-market exposure estimates from July 2015 through March 31, 2021, on patients that have received at least one dose administration of the product. The number of patients receiving at least one administration is estimated using worldwide unit sales data, prescription claims data, and applying utilization assumptions to calculate the unique number of patients. Sources include Amgen Finance Electronic Data Warehouse, IQVIA prescription claims, and Marketscan claims data. The estimates assume patient self-administration based on filled prescriptions.3
†Includes patients randomized to Repatha® or placebo.1
Explore Repatha® clinical evidence in the FOURIER, EVACS, and EVOPACS trials
Learn more
Find out about the access and affordability of Repatha® for your patients
Learn moreReferences: 1. Repatha® (evolocumab) prescribing information, Amgen. 2. Data on file, Amgen; [1]; 2021. 3. Data on file, Amgen; [2]; 2021.